Valganciclovir医保报销吗？

The main ingredient of Valganciclovir Hydrochloride Tablets () is valganciclovir hydrochloride. The currently approved indications include induction treatment of CMV retinitis, maintenance treatment of CMV retinitis and prevention of CMV infection in transplant patients. The safety and efficacy of Valganciclovir treatment were verified in two different trials: The antiviral effect of Valganciclovir was clinically confirmed by the treatment of AIDS patients with newly diagnosed retinitis (clinical study WV15376). The detection rate of CMV virus decreased from 46% (32/69) to 7% (4/55) after 4 weeks of treatment with Valganciclovir, and the U.S. Food and Drug Administration (FDA) approved the increased use of Valganciclovir in adult kidney transplant patients at high risk for cytomegalovirus (CMV) disease. The supplemental approval is based on data that longer-term prophylactic treatment with valganciclovir hydrochloride tablets (Valganciclovir) reduced the incidence of CMV disease in high-risk adult kidney transplant patients from 36.8% (for patients treated for 100 days) to 16.8% (for patients treated for 200 days) one year after receiving a kidney transplant (p <0.0001).1.2 The overall safety of Valganciclovir hydrochloride tablets (Valganciclovir) does not change when prophylaxis is extended in high-risk renal transplant patients.

Valganciclovir hydrochloride tablets (Valganciclovir) were launched in China in 2006. Each box sells for US$2,250 and does not support medical insurance reimbursement. Due to economic pressure, more and more patients are choosing valganciclovir hydrochloride tablets (valganciclovir hydrochloride) launched in India, which is also Roche's original drug and sells for only US$750.